197644-06-7

Upstream product

• 197643-98-4 (S)-(+)-α-acetamido-4-methoxy-α-methylbenzeneacetic acid 
• 170689-16-4 (S)-2-Amino-2-(4-methoxy-phenyl)-propionic acid ethyl ester 
• 74279-63-3 2-(4-methoxyphenyl)-2-methylglycine 
• 170688-63-8 (S)-(+)-2-methyl-2-(4-methoxyphenyl)glycine 
• 22927-78-2 5-(4-methoxyphenyl)-5-methyl-2,4-imidazolidinedione 
• 20074-79-7 diethyl (4-aminobenzyl)phosphonate 
• 197644-03-4 (S)-2-[(R)-2-(4-Benzyloxy-3-methanesulfonylamino-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-ethylamino]-2-(4-methoxy-phenyl)-propionic acid ethyl ester 
• 197644-04-5 (S)-2-[(R)-2-(4-Benzyloxy-3-methanesulfonylamino-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-ethylamino]-2-(4-methoxy-phenyl)-propionic acid 

Relevant academic research and scientific papers

BMS-201620: A selective beta 3 agonist

A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human β3 adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent β3 full agonist (Ki=93nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation.